Want to see DHR full AI Analyst Report?
DHR Stock Chart & Stats
$194.75
-$1.72(-0.72%)
At close: 4:00 PM EST
$194.75
-$1.72(-0.72%)
Day’s Range― - ―
52-Week Range$160.93 - $242.80
Previous CloseN/A
Volume816.38K
Average Volume (3M)4.91M
Market Cap
$134.62B
Enterprise Value$162.35K
Total Cash (Recent Filing)$4.35B
Total Debt (Recent Filing)$26.56B
Price to Earnings (P/E)33.9
Beta0.77
Next Earnings
Oct 27, 2026EPS Estimate
1.93Next Dividend Ex-DateN/A
Dividend Yield0.75%
Share Statistics
EPS (TTM)5.65
Shares Outstanding702,986,100
10 Day Avg. Volume7,236,731
30 Day Avg. Volume4,912,515
Financial Highlights & Ratios
PEG Ratio-9.26
Price to Book (P/B)3.08
Price to Sales (P/S)6.59
P/FCF Ratio30.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$219.78Price Target Upside12.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)8.46
Revenue Forecast (FY)$25.72B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowConsistent, high free cash flow generation provides durable funding for reinvestment, M&A, and shareholder returns. Over 80% FCF conversion of earnings supports sustained capital deployment and reduces reliance on external financing, bolstering long-term financial resilience.
Recurring Revenue ModelA business model anchored in consumables, reagents, services and software creates sticky, repeatable revenue streams. Installed-base-driven purchases and recurring contracts provide predictable demand and margin support, enhancing revenue visibility and long-term customer retention.
Balance Sheet FlexibilityManageable leverage and demonstrated access to long-term, low-cost financing preserve strategic optionality. The ability to issue multi-year notes while maintaining covenants supports M&A, buybacks and working capital needs without materially stressing the capital structure over the medium term.
Bears Say
Slower Revenue & Margin NormalizationA multi-year step-down in top-line growth and normalized profitability reduces earnings leverage and long-term return on invested capital. Slower revenue expansion constrains organic growth optionality and means future EPS gains may rely more on M&A or aggressive cost actions to restore prior margin levels.
Bioprocessing Shipment Timing RiskLarge customer shipment timing can create multi-quarter revenue rebasings and reduce visibility. In bioprocessing, delayed capital and consumable orders can defer downstream recurring consumable demand, making near-term growth lumpy and complicating capacity and inventory planning.
Respiratory Testing HeadwindReduced respiratory testing volumes materially affect mix and revenue growth in diagnostics, pressuring margins where higher-margin non-respiratory volumes may not fully offset declines. Prolonged lower respiratory demand could dampen segment growth and constrain near-term margin expansion.
Danaher News
DHR FAQ
What was Danaher Corporation’s price range in the past 12 months?
Danaher Corporation lowest stock price was $160.93 and its highest was $242.80 in the past 12 months.
What is Danaher Corporation’s market cap?
Danaher Corporation’s market cap is $134.62B.
When is Danaher Corporation’s upcoming earnings report date?
Danaher Corporation’s upcoming earnings report date is Oct 27, 2026 which is in 94 days.
How were Danaher Corporation’s earnings last quarter?
Danaher Corporation released its earnings results on Jul 21, 2026. The company reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.851 by $0.089.
Is Danaher Corporation overvalued?
According to Wall Street analysts Danaher Corporation’s price is currently Undervalued.
Does Danaher Corporation pay dividends?
Danaher Corporation pays a Quarterly dividend of $0.4 which represents an annual dividend yield of 0.75%. See more information on Danaher Corporation dividends here
What is Danaher Corporation’s EPS estimate?
Danaher Corporation’s EPS estimate is 1.93.
How many shares outstanding does Danaher Corporation have?
Danaher Corporation has 702,986,100 shares outstanding.
What happened to Danaher Corporation’s price movement after its last earnings report?
Danaher Corporation reported an EPS of $1.94 in its last earnings report, beating expectations of $1.851. Following the earnings report the stock price went down -10.989%.
Which hedge fund is a major shareholder of Danaher Corporation?
Currently, no hedge funds are holding shares in DHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Danaher Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$219.78 (12.85% Upside)
$219.78 (12.85% Upside)
Blogger Sentiment
Bullish
DHR Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $237.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Bullish
Bullish news 70%
Bearish news 30%
Bearish news 30%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.00%
12-Months-Change
Fundamentals
Return on Equity
0.75%
Trailing 12-Months
Asset Growth
13.17%
Trailing 12-Months
Company Description
Danaher Corporation
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
DHR Revenue Breakdown
29.68% Biotechnology
29.85% Life Sciences
40.46% Diagnostics
DHR Stock 12 Month Forecast
Average Price Target
$219.78
▲(12.85% Upside)
Technical Analysis
Ownership Overview
3.92% Insiders
26.75% Mutual Funds
1.66% Other Institutional Investors
48.01% Public Companies and Individual Investors